July 2026– date –
-
Cell Therapy’s High Cost Rooted in Culture Flask Cytokine Strategy, Driving Shift to Quality over Quantity
Cell & Gene Therapy Review Global Overview A significant portion of cell therapy's cost problem originates in the culture flask, emphasizing the profound impact of cytokine strategy on cell quality and manufacturing economics. The focus ... -
MaxCyte & VectorBuilder Partner on Virus-Free Gene Delivery Platform for Ex Vivo Cell Therapies, Boosting CAR T-Cell Manufacturability
BioProcess International USA Overview CDMO VectorBuilder and MaxCyte have partnered to develop a virus-free gene delivery platform for ex vivo cell therapies, including CAR T cells. This collaboration integrates VectorBuilder's 'MiniVec'... -
Lonza Expands Collaboration with Major US Biopharma, Secures Commercial Production for Two Biologics Programs
Lonza Switzerland Overview Lonza has expanded its strategic collaboration with a leading US biopharmaceutical company, securing commercial production for two biologics programs with options for two more. This expansion reflects robust de... -
Market Report: US Autologous CAR-T Cell Therapy Process Optimization Market Driven by Efficiency & Cost Reduction Needs
Intel Market Research USA Overview This article summarizes the "United States Autologous CART Cell Therapy Process Optimization Market Outlook 2026-2034" report. The US autologous CAR-T cell therapy process optimization market is driven ... -
arXiv Paper: Raman Data Fusion & ML Improve Cell Culture Process Forecasting Accuracy
arXiv USA Overview A new arXiv paper introduces a multipath adaptive gated bottleneck latent ODE with Raman data fusion, significantly improving cell culture process forecasting accuracy, evaluated on fed-batch 5L bioreactor runs. The re... -
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL スペイン Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments.... -
Biologics Outsourcing Redefined: Modality Expertise & End-to-End Integration Key for Partnerships
Bioprocess Online USA Overview Biologics manufacturing outsourcing is evolving into strategic partnerships focused on modality expertise, regulatory excellence, and end-to-end integration, moving beyond mere cost savings. To support incr... -
CDMO Signal Ranks Top FDA & GMP-Compliant Lentiviral Vector Manufacturing CDMOs
CDMO Signal Global Overview CDMO Signal has released a ranking of top Lentiviral Vector (LVV) CDMOs, crucial for ex vivo gene therapy, based on FDA inspection history, GMP certification, clinical program activity, and capacity. LVVs are ... -
Precision Fermentation Targets Production Cost & Scale-Up Challenges for Sustainable Food Industry
MyTeknologia Global Overview Precision fermentation, an advanced method for producing specific molecules in controlled bioreactor systems, offers a new pathway for a sustainable food industry. This technology holds the potential to produ... -
Bioneer Unveils BioSPHEER™: A 3D Cancer Model Revolutionizing Solid Tumor Drug Discovery
Bioneer デンマーク Overview Bioneer has launched BioSPHEER™, an innovative in vitro 3D cancer platform designed to significantly enhance drug efficacy prediction for solid tumors. This platform generates high-fidelity tumor models by ass...
